Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), today announced that it is offering to sell, subject to market and other conditions, shares of its common stock in an underwritten offering. Cyclacel also expects to grant the underwriters a 30-day option to purchase additional shares of common stock to cover overallotments, if any. All of the shares in this offering are to be sold by Cyclacel.
Cyclacel Pharmaceuticals is a development-stage biopharmaceutical company engaged in the development and commercialization of drugs to treat human cancers and other diseases. Co.'s clinical development activities are focused on sapacitabine in the indications of acute myeloid leukemia in the elderly, myelodysplastic syndromes, and non-small cell lung cancer. Co.'s other oncology development programs include: Seliciclib, CYC116, CYC065, and CYC800 (Plk). In addition, Co. has rights to sell and distribute three products in the U.S. and Canada used primarily to manage the effects of radiation or chemotherapy in cancer patients: Xclair® Cream, Numoisyn® Liquid and Numoisyn® Lozenges.
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20
minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.